Journal of Cancer Research and Immuno-Oncology is a fast-developing open access journal in the field of cancer research. It is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members.. Journal of Cancer Research and Immuno-Oncology covers a broad scope for the authors to make their valuable contributions in cancer biology, tumor, radiology, metastatis, cancer immunotherapy, oncology, radiation therapy etc.

This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of latest cancer research and Immuno-Oncology Abstracts and full texts of all articles published by Journal of Cancer Research and Immuno-Oncology are freely accessible to everyone.

Journal of Cancer Research and Immuno-Oncology welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately 7 days after acceptance.

Journal of Cancer Research and Immuno-Oncology is the Council Contributor Member for Council of Science Editors (CSE) and follows the CSEs slogan Education, Ethics, and Evidence for Editors

One of the newer classes of targeted cancer therapeutics is monoclonal antibodies. Monoclonal antibody therapeutics are a successful and rapidly expanding drug class due to their high specificity, activity, favourable pharmacokinetics, and standardized manufacturing processes. Antibodies are capable of recruiting the immune system to attack cancer cells through complement-dependent cytotoxicity or antibody dependent cellular cytotoxicity.

 In an ideal scenario the initial tumor cell destruction induced by administration of a therapeutic antibody can result in uptake of tumor associated antigens by antigen-presenting cells, establishing a prolonged memory effect. Mechanisms of direct tumor cell killing by antibodies include antibody recognition of cell surface bound enzymes to neutralize enzyme activity and signaling, or induction of receptor agonist or antagonist activity. Both approaches result in cellular apoptosis.

In another and very direct approach, antibodies are used to deliver drugs to target cells and cause cell death. Such antibody drug conjugates (ADCs) direct cytotoxic compounds to tumor cells, after selective binding to cell surface antigens, internalization, and intracellular drug release. Efficacy and safety of ADCs for cancer therapy has recently been greatly advanced based on innovative approaches for site-specific drug conjugation to the antibody structure. This technology enabled rational optimization of function and pharmacokinetics of the resulting conjugates, and is now beginning to yield therapeutics with defined, uniform molecular characteristics, and unprecedented promise to advance cancer treatment.

Interested can submit their manuscript through online portal

Submit manuscript at https://www.longdom.org/submissions/cancer-research-immuno-oncology.htmll or send as an e-mail attachment to the Editorial Office at [email protected]

Media contact:

Maegan Smith

Managing Editor

Journal of Cancer Research and Immuno-Oncology

Mail ID: [email protected]       

WhatsApp no: + 1-504-608-2390